Partnership to End Addiction supports reducing barriers to effective substance use disorder treatment, including eliminating the DATA 2000 waiver required to prescribe buprenorphine. Nonetheless, we stress that other policy changes are needed to ensure more people receive effective care. The buprenorphine requirement should be eliminated because (1) it has failed to meet its ostensible purpose, which is to prevent unscrupulous prescribing and diversion and (2) it has limited access to an effective opioid addiction medication during an unprecedented opioid epidemic. With 128 people dying every day from an opioid overdose, access to effective treatment is more critical now than ever before. The current waiver requirement is completely incompatible with the goal to increase access to evidence-based treatment for opioid use disorder (OUD).
Instead of reducing diversion, the waiver requirement has contributed to diversion of buprenorphine for self-treatment because treatment is unavailable. It is also notable that the DEA has not used waiver requirements to reduce diversion of any other medication, including prescription opioids where diversion of such medications has resulted in unquestionable societal risk and harm. The differential treatment of buprenorphine versus other narcotic pain relievers is driven by stigma rather than science and results in discrimination against patients with OUD. There is no clinical justification for imposing a patient limit, training and administrative requirements associated with prescribing buprenorphine. In fact, providers who prescribe oxycodone, a DEA Schedule II drug, or who prescribe methadone or buprenorphine for pain are not subject to these same restrictions. The only difference is that the patients to whom buprenorphine is prescribed are undergoing treatment for addiction. Given the effectiveness of buprenorphine in treating OUD, a life-threatening disorder, and the limited access to care, we find it unconscionable that the government would single out this treatment with patient limitations.
Efforts to reduce unscrupulous prescribing have, in fact, reduced overall prescribing of buprenorphine. A very small number of providers have obtained the waiver and fewer actually prescribe buprenorphine. The waiver requirement has created the perception among providers that it is difficult or challenging to treat SUD, perpetuating stigma and discouraging providers from engaging in the practice. Increasing access to evidence-based SUD treatment is essential to address our nation’s addiction crisis and it is evident that the buprenorphine waiver requirement obstructs this goal.
While we support eliminating the requirement, we understand that, alone, it is insufficient to increase access to buprenorphine and other effective SUD care. Eliminating the waiver requirement must be accompanied by efforts to increase SUD training for health care providers and provide adequate reimbursement.
Despite the prevalence of the disease, health care providers receive very little training in SUD and this has left the health care system woefully unprepared to deal with addiction. To rectify this and increase the number of providers offering evidence-based care such as buprenorphine, addiction training must be incorporated into medical school curricula. Congress authorized a grant program for medical schools and teaching hospitals to establish curricula for prescribing medications for addiction treatment in the SUPPORT Act. This program should be fully funded to encourage and support medical schools to provide SUD training and better equip future generations of health care providers to treat addiction like any other disease.
In addition to medical school training, ongoing training should be required for health care providers through continuing medical education and licensing requirements. Providers also need support and guidance from more experienced providers to consult on complex cases as well as support staff, such as nurses, social workers, and peers to meet patients’ needs adequately.
Under the current waiver requirement, prescribers are required to have capacity to refer patients to counseling and other ancillary services. This requirement assumes that these services are accessible; yet, there are severe shortages of behavioral health services across the country. A requirement to refer to services that do not exist may reduce prescribing. Providers often cite lack of availability of behavioral health services as a barrier to prescribing buprenorphine. Policy changes other than a referral requirement are needed to ensure patients have access to behavioral counseling and other ancillary services.
To ensure prescribers can hire appropriate support staff and to increase availability of ancillary services, the reimbursement rate must be increased. One possible reason for the shortage of quality behavioral health services is low insurance participation and reimbursement. Lack of insurance coverage is also cited as a barrier to prescribing buprenorphine. A number of states have increased access to and quality of buprenorphine treatment by changing reimbursement policies in Medicaid. These strategies should be replicated on the national level and applied in other insurance products, to ensure adequate access to effective addiction treatment. In addition, the SUPPORT Act requires the development of recommendations for improving coverage and payment for SUD medications in Medicare. Establishing an adequate Medicare reimbursement rate for SUD treatment is an important way to influence other payers to revise their rates.
In summary, removing the buprenorphine wavier requirement is an important policy change but it must be accompanied by other innovative policies to significantly increase access to effective OUD treatment. Center on Addiction supports eliminating the DATA 2000 waiver requirement, together with funding and requirements for provider training and increased reimbursement rates for SUD treatment, to increase access to life-saving care.